Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study

William J. Sandborn*, Jean Frédéric Colombel, Subrata Ghosh, Bruce E. Sands, Gerald Dryden, Xavier Hébuterne, Rupert W. Leong, Brian Bressler, Thomas Ullman, Peter L. Lakatos, Walter Reinisch, Li An Xu, Allison Luo

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Eldelumab [Anti-IP-10] induction therapy for ulcerative colitis: A randomised, placebo-controlled, phase 2b study'. Together they form a unique fingerprint.

Medicine & Life Sciences